FATE
Price
$0.69
Change
-$0.08 (-10.39%)
Updated
Apr 3, 04:59 PM (EDT)
Capitalization
88.24M
27 days until earnings call
OCX
Price
$2.90
Change
-$0.06 (-2.03%)
Updated
Apr 3, 01:50 PM (EDT)
Capitalization
24.2M
Ad is loading...

FATE vs OCX

Header iconFATE vs OCX Comparison
Open Charts FATE vs OCXBanner chart's image
Fate Therapeutics
Price$0.69
Change-$0.08 (-10.39%)
Volume$48.64K
Capitalization88.24M
Oncocyte
Price$2.90
Change-$0.06 (-2.03%)
Volume$100
Capitalization24.2M
FATE vs OCX Comparison Chart
Loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FATE vs. OCX commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Hold and OCX is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (FATE: $0.77 vs. OCX: $2.95)
Brand notoriety: FATE and OCX are both not notable
FATE represents the Biotechnology, while OCX is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: FATE: 160% vs. OCX: 68%
Market capitalization -- FATE: $88.24M vs. OCX: $24.2M
FATE [@Biotechnology] is valued at $88.24M. OCX’s [@Medical Specialties] market capitalization is $24.2M. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B. The average market capitalization across the [@Medical Specialties] industry is $8.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileOCX’s FA Score has 0 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • OCX’s FA Score: 0 green, 5 red.
According to our system of comparison, OCX is a better buy in the long-term than FATE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 4 TA indicator(s) are bullish while OCX’s TA Score has 4 bullish TA indicator(s).

  • FATE’s TA Score: 4 bullish, 4 bearish.
  • OCX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both FATE and OCX are a good buy in the short-term.

Price Growth

FATE (@Biotechnology) experienced а -9.85% price change this week, while OCX (@Medical Specialties) price change was -7.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.57%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -14.76%.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.10%. For the same industry, the average monthly price growth was +1.89%, and the average quarterly price growth was +1.69%.

Reported Earning Dates

FATE is expected to report earnings on Apr 30, 2025.

OCX is expected to report earnings on Nov 09, 2023.

Industries' Descriptions

@Biotechnology (-8.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Medical Specialties (-4.10% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($88.2M) has a higher market cap than OCX($24.2M). OCX YTD gains are higher at: 23.950 vs. FATE (-53.333). OCX has higher annual earnings (EBITDA): -10.44M vs. FATE (-176.58M). FATE has more cash in the bank: 279M vs. OCX (14.2M). OCX has less debt than FATE: OCX (3.07M) vs FATE (85.3M). FATE has higher revenues than OCX: FATE (13.6M) vs OCX (1.46M).
FATEOCXFATE / OCX
Capitalization88.2M24.2M364%
EBITDA-176.58M-10.44M1,691%
Gain YTD-53.33323.950-223%
P/E RatioN/A4.56-
Revenue13.6M1.46M930%
Total Cash279M14.2M1,965%
Total Debt85.3M3.07M2,775%
FUNDAMENTALS RATINGS
FATE vs OCX: Fundamental Ratings
FATE
OCX
OUTLOOK RATING
1..100
5563
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
56
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
9643
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (13) in the Biotechnology industry is somewhat better than the same rating for OCX (56) in the Medical Specialties industry. This means that FATE’s stock grew somewhat faster than OCX’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as OCX (100) in the Medical Specialties industry. This means that FATE’s stock grew similarly to OCX’s over the last 12 months.

FATE's SMR Rating (97) in the Biotechnology industry is in the same range as OCX (99) in the Medical Specialties industry. This means that FATE’s stock grew similarly to OCX’s over the last 12 months.

OCX's Price Growth Rating (43) in the Medical Specialties industry is somewhat better than the same rating for FATE (96) in the Biotechnology industry. This means that OCX’s stock grew somewhat faster than FATE’s over the last 12 months.

OCX's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as FATE (100) in the Biotechnology industry. This means that OCX’s stock grew similarly to FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FATEOCX
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
67%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 23 days ago
85%
Bullish Trend 8 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Ad is loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OCX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CPSH1.590.04
+2.58%
CPS Technologies Corp
XOMA19.780.48
+2.49%
XOMA Royalty Corporation
VRT77.111.84
+2.44%
Vertiv Holdings Co
BOX31.470.15
+0.48%
BOX
GB7.380.01
+0.14%
Global Blue Group Holding AG

OCX and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCX has been loosely correlated with STRRP. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if OCX jumps, then STRRP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCX
1D Price
Change %
OCX100%
-1.67%
STRRP - OCX
37%
Loosely correlated
N/A
FATE - OCX
31%
Poorly correlated
+1.70%
GOSS - OCX
29%
Poorly correlated
-1.59%
BMRN - OCX
29%
Poorly correlated
+0.56%
CRIS - OCX
28%
Poorly correlated
+1.37%
More